BlackRock, Inc. Amends Schedule 13G/A for Tourmaline Bio, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Tourmaline Bio, Inc., reporting a 5.5% ownership of the company's common stock as of September 30, 2025. The filing indicates that BlackRock beneficially owns 1,411,832 shares, with sole voting power over 1,364,933 shares and sole dispositive power over all 1,411,832 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.